Skip to Content
Merck

Key Documents

View All Documentation

T4680

Terazosin hydrochloride

≥98% (TLC), α1-adrenoceptor antagonist, powder

Synonym(s):

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C19H25N5O4 · HCl
CAS Number:
63074-08-8
Molecular Weight:
423.89
UNSPSC Code:
12352200
PubChem Substance ID:
24278740
NACRES:
NA.77
MDL number:
MFCD00467965
Assay:
≥98% (TLC)
Form:
powder
Quality level:
200
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Terazosin hydrochloride, ≥98% (TLC), powder

Quality Level

200

assay

≥98% (TLC)

form

powder

color

white to off-white

solubility

H2O: soluble 19.60-20.40 mg/mL, clear, colorless to faintly yellow, methanol: 20 mg/mL, clear, colorless, ethanol: 4 mg/mL

originator

Abbott

SMILES string

Cl[H].COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4

InChI

1S/C19H25N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H

InChI key

IWSWDOUXSCRCKW-UHFFFAOYSA-N

Gene Information

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146)

General description

Terazosin hydrochloride is used to treat hypertension and benign prostatic hyperplasia (BPH). It is metabolised in the liver. It might be associated with dizziness, headache and asthenia. Terazosin hydrochloride is linked to acute generalized exanthematous pustulosis.

Application

Terazosin hydrochloride has been used for orthogonality and similarity analysis using reversed-phase chromatographic studies5. Furthermore, terazosin has also been used for the evaluation of chemometric techniques to determine orthogonality and similarity in chromatographic methods6.

Biochem/physiol Actions

α1-adrenoceptor antagonist.

Features and Benefits

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Terazosin hydrochloride is soluble in water at 19.60 - 20.40 mg/ml and yields a clear, colorless to faint yellow solution. It is also soluble in ethanol at 4 mg/ml. Furthermore, the product is soluble in methanol at 20 mg/ml, with heat as needed, and yields a clear, colorless solution.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000453616
0000453615
0000453616
0000453615
0000432990

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

E Van Gyseghema et al.
Journal of chromatography. A, 1074(1-2), 117-131 (2005-06-09)
The starting point of this study was a current set of 32 chromatographic systems used to select initial conditions for method development to determine the impurity profile of a drug. The system exhibiting the best selectivity is then selected for
A A Hancock et al.
Journal of receptor and signal transduction research, 15(7-8), 863-885 (1995-09-01)
Terazosin and its enantiomers, antagonists of alpha 1-adrenoceptors, were studied in radioligand binding and functional assays to determine relative potencies at subtypes of alpha 1- and alpha 2-adrenoceptors in vitro. The racemic compound and its enantiomers showed high and apparently
R McCarty et al.
Hypertension (Dallas, Tex. : 1979), 27(5), 1115-1120 (1996-05-01)
To examine the contribution of the sympathetic nervous system to the development of hypertension, we injected spontaneously hypertensive rat (SHR) pups and normotensive Wistar-Kyoto rat (WKY) pups twice daily with saline (1.0 mL/kg SC) or terazosin (0.5 mg/kg SC), an
View All Related Papers